Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 4:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 392 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pulmonary Artery Hypertension Clear all
Completed No phase listed Observational
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Pulmonary Arterial Hypertension - Lung Perfusion Scans
Other
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Mar 8, 2010 · Synced May 22, 2026, 4:13 AM EDT
Completed Phase 4 Interventional Results available
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Ambrisentan, Placebo, Sildenafil, Tadalafil
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
16 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
30
States / cities
Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2012 · Synced May 22, 2026, 4:13 AM EDT
Recruiting Not applicable Interventional
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
blood draw, Short Performance Physical Battery, Grip strength test, Six minute walk test, Chest CT scan, Dual-Energy X-ray Absorptiometry Scan, Activity monitoring, 24 hour diet recall, Echocardiogram, Quality of Life Questionnaire (emPHasis 10), International Physical Activity Questionnaire Short Form (IPAQ-SF), Low resistance exercise intervention
Diagnostic Test · Radiation · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced May 22, 2026, 4:13 AM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
nab-sirolimus
Drug
Lead sponsor
Aadi Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
6
States / cities
Tucson, Arizona • Torrance, California • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2024 · Synced May 22, 2026, 4:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Elafin, Placebo
Drug
Lead sponsor
Roham T. Zamanian
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 14, 2024 · Synced May 22, 2026, 4:13 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Oral treprostinil (UT-15C) Sustained Release Tablets, Placebo
Drug · Other
Lead sponsor
United Therapeutics
Industry
Eligibility
12 Years to 75 Years
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
43
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced May 22, 2026, 4:13 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
CT Pulmonary Angiography Scan
Diagnostic Test
Lead sponsor
Prisma Health-Upstate
Other
Eligibility
Not listed
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced May 22, 2026, 4:13 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Scleroderma Associated Pulmonary Arterial Hypertension, Appetite Suppressant Associate PAH
Interventions
Not listed
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Up to 90 Years
Enrollment
1,899 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2032
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced May 22, 2026, 4:13 AM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Unaffected Mutation Carriers: Healthy Participants With a Known BMPR2 Gene Mutation and Normal Pulmonary Pressure and RV Function on Echo, Healthy Individuals With no Cardiopulmonary Disease
Interventions
Not listed
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
15 Years to 80 Years
Enrollment
150 participants
Timeline
2022 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced May 22, 2026, 4:13 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Pulmonary Hypertension, Sickle Cell Disease
Interventions
macitentan
Drug
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced May 22, 2026, 4:13 AM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension, Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
Pulmonary Hypertension Association, Inc.
Other
Eligibility
0 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
52
States / cities
Phoenix, Arizona • Sacramento, California • San Francisco, California + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced May 22, 2026, 4:13 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Ultrasound Doppler
Radiation
Lead sponsor
Echosense Ltd.
Industry
Eligibility
Not listed
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2021
U.S. locations
2
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 22, 2022 · Synced May 22, 2026, 4:13 AM EDT
Not listed Phase 4 Interventional
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Spironolactone, Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2015 · Synced May 22, 2026, 4:13 AM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Treprostinil Injectable Product, Riociguat Pill
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced May 22, 2026, 4:13 AM EDT
Withdrawn Phase 3 Interventional
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
UT-15C 1 mg, UT-15C 0.25 mg, UT-15C 5 mg, Placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
26
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2013 · Synced May 22, 2026, 4:13 AM EDT
Withdrawn Not applicable Interventional
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
CT imaging, functional PET imaging
Other
Lead sponsor
Robert Scott Harris, M.D.
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 14, 2016 · Synced May 22, 2026, 4:13 AM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Seralutinib, Gereic Dry Powder Inhaler
Drug · Device
Lead sponsor
GB002, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
33
States / cities
Fresno, California • Los Angeles, California • Sacramento, California + 26 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced May 22, 2026, 4:13 AM EDT
Terminated Phase 3 Interventional Results available
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Interventions
Sitaxsentan, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
16 Years to 80 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
32
States / cities
Fountain Valley, California • Mather, California • Sacramento, California + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2015 · Synced May 22, 2026, 4:13 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
No Intervention
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 100 Years
Enrollment
1,195 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2029
U.S. locations
7
States / cities
Tucson, Arizona • Baltimore, Maryland • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2025 · Synced May 22, 2026, 4:13 AM EDT
Recruiting Not applicable Interventional
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
mHealth Intervention, Usual Care
Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
10 Years to 21 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced May 22, 2026, 4:13 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced May 22, 2026, 4:13 AM EDT
Withdrawn Phase 4 Interventional
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis
Interventions
bosentan
Drug
Lead sponsor
Rajan Saggar
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2018 · Synced May 22, 2026, 4:13 AM EDT
Terminated Phase 2 Interventional
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
sildenafil
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 7, 2013 · Synced May 22, 2026, 4:13 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Interventions
PRX-08066
Drug
Lead sponsor
Epix Pharmaceuticals, Inc.
Industry
Eligibility
25 Years to 79 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
19
States / cities
Anniston, Alabama • Phoenix, Arizona • Sacramento, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 28, 2008 · Synced May 22, 2026, 4:13 AM EDT